Belatacept
- Generic Name
- Belatacept
- Brand Names
- Nulojix
- Drug Type
- Biotech
- CAS Number
- 706808-37-9
- Unique Ingredient Identifier
- E3B2GI648A
- Background
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
- Indication
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
- Associated Conditions
- Kidney Transplant Rejection
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
- Conditions
- Kidney Transplant Rejection
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Target Recruit Count
- 100
- Registration Number
- NCT06918990
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Belatacept in Heart Transplantation
- Conditions
- Heart Transplant
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-02-11
- Target Recruit Count
- 66
- Registration Number
- NCT06478017
- Locations
- 🇺🇸
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146), Los Angeles, California, United States
🇺🇸Tampa General Hospital (Site # 71150), Tampa, Florida, United States
🇺🇸NYU Langone Health (Site # 71177), New York, New York, United States
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
- Conditions
- HBVLiver TransplantationKidney Transplantation
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 66
- Registration Number
- NCT06307808
- Locations
- 🇫🇷
Grenoble University Hospital, Grenoble, Aura, France
Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>
- Conditions
- Kidney Diseases
- Interventions
- Drug: anticalcineurins
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 44
- Registration Number
- NCT06291077
Advancing Transplantation Outcomes in Children
- Conditions
- Kidney Transplant
- Interventions
- Drug: Anti-Thymocyte Globulin (ATG)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-02-26
- Target Recruit Count
- 200
- Registration Number
- NCT06055608
- Locations
- 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
- Conditions
- Kidney Transplant Infection
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 28
- Registration Number
- NCT05708534
A Study of TCD601 in de Novo Renal Transplant Recipients
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 90
- Registration Number
- NCT05669001
- Locations
- 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
- Conditions
- Chronic Kidney Failure
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05562869
- Locations
- 🇫🇷
CHU Nantes, Nantes, Loire Atlantique, France
Novel Desensitization Kidney Transplantation
- Conditions
- Kidney TransplantationEnd Stage Kidney Disease (ESRD)
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 5
- Registration Number
- NCT05345717
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Carfilzomib and Belatacept for Desensitization
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2025-02-20
- Target Recruit Count
- 15
- Registration Number
- NCT05017545
- Locations
- 🇺🇸
Duke Transplant Center, Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.